Biomarkers in Barrett's Esophagus: Role in Diagnosis, Risk Stratification, and Prediction of Response to Therapy

Gastroenterology Clinics of North America

Volumn 44, Issue 2, 2015, Pages 373-390

  Bansal, Ajay ^a   Fitzgerald, Rebecca C ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Barrett's esophagus; Biomarkers; Diagnosis; Esophageal adenocarcinoma; High grade dysplasia; Response to therapy; Risk stratification; Screening

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; CYTOKINE; GASTRIN; GROWTH FACTOR; MESOTHELIN; MICRORNA; PROTEIN P53; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; PEPTIDE; TFF3 PROTEIN, HUMAN;

AUTOFLUORESCENCE IMAGING; BARRETT ESOPHAGUS; BLOOD ANALYSIS; CHROMOSOME DELETION; CYTOLOGY; DNA CONTENT; DNA METHYLATION; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC GAIN; HUMAN; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ANEUPLOIDY; BLOOD; GENETICS; METABOLISM; PATHOLOGY;

ANEUPLOIDY; BARRETT ESOPHAGUS; BIOMARKERS; DNA METHYLATION; HUMANS; MICRORNAS; PEPTIDES; RISK ASSESSMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929957512     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.02.008     Document Type: Review

References (86)

1. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014, 63:7-42.
2. Wani S., Falk G., Hall M., et al. Patients With nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011, 9:220-227.
3. Sharma P. Clinical practice. Barrett's esophagus. NEngl J Med 2009, 361:2548-2556.
4. Kadri S.R., Lao-Sirieix P., O'Donovan M., et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010, 341:c4372.
5. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
6. Zaidi A.H., Gopalakrishnan V., Kasi P.M., et al. Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer 2014, 120(24):3902-3913.
7. Feero W.G., Guttmacher A.E., Collins F.S. Genomic medicine-an updated primer. NEngl J Med 2010, 362:2001-2011.
8. Lao-Sirieix P., Boussioutas A., Kadri S.R., et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009, 58:1451-1459.
9. Ross-Innes C.S., Debiram-Beecham I., O'Donovan M., et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med 2015, 12:e1001780.
10. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
11. Fassan M., Volinia S., Palatini J., et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2010, 129(7):1661-1670.
12. Bansal A., Lee I.H., Hong X., et al. Discovery and validation of Barrett's esophagus MicroRNA transcriptome by next generation sequencing. PLoS One 2013, 8:e54240.
13. Fassan M., Volinia S., Palatini J., et al. MicroRNA expression profiling in the histological subtypes of Barrett's metaplasia. Clin Transl Gastroenterol 2013, 4:e34.
14. Garman K.S., Owzar K., Hauser E.R., et al. MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer. Dig Dis Sci 2013, 58:3178-3188.
15. Leidner R.S., Ravi L., Leahy P., et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012, 51:473-479.
16. Saad R., Chen Z., Zhu S., et al. Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS One 2013, 8:e64463.
17. Bansal A., Hong X., Lee I.H., et al. MicroRNA expression can be a promising strategy for the detection of Barrett's Esophagus: A pilot study. Clin Trans Gastroenterol 2014, [in press]. 10.1038/ctg.2014.17.
18. American Gastroenterological Association, Spechler S.J., Sharma P., et al. American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. Gastroenterology 2011, 140:1084-1091.
19. Wong D.J., Paulson T.G., Prevo L.J., et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61:8284-8289.
20. Kaz A.M., Wong C.J., Luo Y., et al. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics 2011, 6:1403-1412.
21. Moinova H., Leidner R.S., Ravi L., et al. Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev 2012, 21:594-600.
22. Smith E., De Young N.J., Pavey S.J., et al. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer 2008, 7:75.
23. Xu E., Gu J., Hawk E.T., et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 2013, 34:2750-2756.
24. Jin Z., Cheng Y., Olaru A., et al. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 2008, 123:2331-2336.
25. Alvarez H., Opalinska J., Zhou L., et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 2011, 7:e1001356.
26. Iyer P.G., Clemens M.A., Yab T.C., et al. Highly discriminant methylated DNA markers for detection of Barrett's esophagus. Gastroenterology 2013, 144:S-684.
27. Groome M., Lindsay J., Ross P.E., et al. Use of oesophageal stress response proteins as potential biomarkers in the screening for Barrett's oesophagus. Eur J Gastroenterol Hepatol 2008, 20:961-965.
28. Shi X.Y., Bhagwandeen B., Leong A.S. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. Am J Clin Pathol 2008, 129:571-577.
29. Fahmy M., Skacel M., Gramlich T.L., et al. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol 2004, 17:588-596.
30. Brankley S.M., Wang K.K., Harwood A.R., et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. JMol Diagn 2006, 8:260-267.
31. Fritcher E.G., Brankley S.M., Kipp B.R., et al. Acomparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol 2008, 39:1128-1135.
32. Wiech T., Nikolopoulos E., Weis R., et al. Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest 2009, 89:385-397.
33. Geppert C.I., Rummele P., Sarbia M., et al. Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade. Br J Cancer 2014, 110:2985-2995.
34. Rauser S., Weis R., Braselmann H., et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007, 13:5115-5123.
35. Rygiel A.M., van Baal J.W., Milano F., et al. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer 2007, 109:1980-1988.
36. Timmer J.L., Rosmolen C.T., Meijer W., et al. AFISH biomarker panel for the prediction of high-grade dysplasia and adenocarcinom in non-dysplastic Barrett's esophagus: results from a long-term prospective cohort study. United European Gastroenterol J 2014, 2(suppl):A1-A131. [abstract].
37. Timmer M.R., Sun G., Gorospe E.C., et al. Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus 2013, 26:574-581.
38. Prasad G.A., Bansal A., Sharma P., et al. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010, 105:1490-1502.
39. Kerkhof M., Steyerberg E.W., Kusters J.G., et al. Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. Cancer Biomark 2008, 4:1-10.
40. Sikkema M., Kerkhof M., Steyerberg E.W., et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol 2009, 104:2673-2680.
41. Kastelein F., Biermann K., Steyerberg E.W., et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013, 62:1676-1683.
42. Bird-Lieberman E.L., Dunn J.M., Coleman H.G., et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012, 143:927-935.e3.
43. Alsner J., Jensen V., Kyndi M., et al. Acomparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008, 47:600-607.
44. Kaye P.V., Haider S.A., James P.D., et al. Novel staining pattern of p53 in Barrett's dysplasia-the absent pattern. Histopathology 2010, 57:933-935.
45. Davelaar A.L., Calpe S., Lau L., et al. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study. Genes Chromosomes Cancer 2015, 54(2):82-90.
46. Weaver J.M., Ross-Innes C.S., Shannon N., et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014, 46:837-843.
47. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001, 96:2839-2848.
48. Yu C., Zhang X., Huang Q., et al. High-fidelity DNA histograms in neoplastic progression in Barrett's esophagus. Lab Invest 2007, 87:466-472.
49. Dunn J.M., Mackenzie G.D., Oukrif D., et al. Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer 2010, 102:1608-1617.
50. Reid B.J., Blount P.L., Rubin C.E., et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992, 102:1212-1219.
51. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000, 95:1669-1676.
52. Li X., Galipeau P.C., Paulson T.G., et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) 2014, 7:114-127.
53. Nones K., Waddell N., Wayte N., et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun 2014, 5:5224.
54. Wong D.J., Barrett M.T., Stoger R., et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997, 57:2619-2622.
55. Schulmann K., Sterian A., Berki A., et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005, 24:4138-4148.
56. Clement G., Braunschweig R., Pasquier N., et al. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. JPathol 2006, 208:100-107.
57. Sato F., Jin Z., Schulmann K., et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One 2008, 3:e1890.
58. Jin Z., Cheng Y., Gu W., et al. Amulticenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009, 69:4112-4115.
59. Wang J.S., Guo M., Montgomery E.A., et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol 2009, 104:2153-2160.
60. Alvi M.A., Liu X., O'Donovan M., et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res 2013, 19:878-888.
61. Feber A., Xi L., Luketich J.D., et al. MicroRNA expression profiles of esophageal cancer. JThorac Cardiovasc Surg 2008, 135:255-260. [discussion: 260].
62. Bansal A., Lee I.H., Hong X., et al. Feasibility of microRNAs as biomarkers for Barrett's esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 2011, 106(6):1055-1063.
63. Revilla-Nuin B., Parrilla P., Lozano J.J., et al. Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg 2013, 257:886-893.
64. Peiro-Chova L., Pena-Chilet M., Lopez-Guerrero J.A., et al. High stability of microRNAs in tissue samples of compromised quality. Virchows Arch 2013, 463:765-774.
65. Maley C.C., Galipeau P.C., Finley J.C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 38:468-473.
66. Merlo L.M., Shah N.A., Li X., et al. Acomprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2010, 3:1388-1397.
67. di Pietro M., Boerwinkel D.F., Shariff M.K., et al. The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus. Gut 2014, 64(1):49-56.
68. Duits L.C., Phoa K.N., Curvers W.L., et al. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut 2014, [Epub ahead of print].
69. Curvers W.L., ten Kate F.J., Krishnadath K.K., et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010, 105:1523-1530.
70. Wani S., Falk G.W., Post J., et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011, 141:1179-1186. 1186.e1.
71. Pasricha S., Bulsiewicz W.J., Hathorn K.E., et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. Clin Gastroenterol Hepatol 2014, 12(11):1840-1847.e1.
72. Prasad G.A., Wang K.K., Halling K.C., et al. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer 2008, 113:470-476.
73. Prasad G.A., Wang K.K., Halling K.C., et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008, 135:370-379.
74. Timmer M.R., Brankley S.M., Gorospe E.C., et al. Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointest Endosc 2014, 80(6):984-991.
75. Lao-Sirieix P., Fitzgerald R.C. Screening for oesophageal cancer. Nature reviews. Net Rev Clin Oncol 2012, 9:278-287.
76. Zhai R., Zhao Y., Su L., et al. Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia 2012, 14:29-33.
77. Zhang J., Bowers J., Liu L., et al. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS One 2012, 7:e30181.
78. Rubenstein J.H., Morgenstern H., McConell D., et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology 2013, 145:1237-1244.e1-5.
79. Mechref Y., Hussein A., Bekesova S., et al. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. JProteome Res 2009, 8:2656-2666.
80. Thrift A.P., Garcia J.M., El-Serag H.B. Amultibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2014, 12:1267-1271.
81. Wang J.S., Varro A., Lightdale C.J., et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol 2010, 105:1039-1045.
82. Rizk N.P., Servais E.L., Tang L.H., et al. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2012, 21:482-486.
83. Bansal A., Hong X., Lee I.H., et al. Serum exosomal microRNA expression can be a novel non-invasive strategy for the screening of Barrett's esophagus. Gastroenterology 2013, 144:S-684.
84. Van Baal J.W., Kestens C., Ten Kate F.T., et al. Comprehensive profiling of plasma MicroRNAs reveals potential biomarkers for Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2014, 146:S-97.
85. Li Y., Jiang Z., Xu L., et al. Stability analysis of liver cancer-related microRNAs. Acta Biochim Biophys Sin (Shanghai) 2011, 43:69-78.
86. Wijnhoven B.P., Hussey D.J., Watson D.I., et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg 2010, 97(6):853-861.